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Abstract 
Background: Glioblastoma stem cells (GSC) have been extensively recognized as a plausible cause of glioblas-
toma resistance to therapy and recurrence resulting in high glioblastoma mortality. Abnormalities in the DNA repair 
pathways might be responsible for the inability of the currently used chemotherapeutics to eliminate the (GSC) 
subpopulation.
Methods: In this work, we compared the expression of sixty DNA repair related genes between primary glioblas-
toma cell cultures and the glioblastoma enriched stem cell primary cultures. MTT test was used to analyze the effect 
of selected drugs and immunofluorescence to evaluate the load of DNA damage.
Results: We found several differentially expressed genes and we identified topoisomerase IIβ (Top2β) as the gene 
with highest up-regulation in GSC. Also among the tested cell lines the expression of Top2β was the highest in 
NCH421k cells, a well-characterized glioblastoma cell line with all the stemness characteristics. On the other hand, 
Top2β expression markedly decreased upon the induction of differentiation by all trans-retinoic acid. Depletion of 
Top2β increased the sensitivity of NCH421k cells to replication stress inducing drugs, such as cisplatin, methyl-meth-
anesulfonate, hydrogen peroxide, and temozolomide. Consistently, we found an increased load of DNA damage and 
increased Chk1 activation upon Top2β depletion in NCH421k cells.
Conclusion: We suggest that Top2β may represent a new target for gene therapy in glioblastoma. In addition, the 
other genes that we found to be up-regulated in GSC versus glioblastoma primary cells should be further investigated 
as glioblastoma theranostics.
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Background
Glioblastoma (GBM) is the most common and aggres-
sive malignancy of the central nervous system. Despite 
major progress in cancer treatment in the last decade, 
GBM remains fatal with 12–15 months median survival 
after diagnosis [1, 2]. Standard therapy currently consists 
of minimal resection, followed by radiotherapy alone or 
in combination with temozolomide. The main cause of 
mortality in GBM patients is the recurrence of the tumor. 
According to the cancer stem cell theory, recurrence is a 
consequence of therapeutics failing to completely elimi-
nate a subpopulation of cancer cells with stem cell char-
acteristic, called cancer stem cells, that have been first 
described in GBM by Singh et al. [3] and Galli et al. [4]. 
Besides in GBM [5, 6], the presence of these cells has 
been confirmed in many tumor types, which has been 
correlated with worse prognosis in breast, head and neck 
and oropharyngeal cancer as well as in glioma [7–10]. 
Several approaches have been suggested to eradicate 
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cancer stem cells, such as induction of differentiation, 
immunotherapy or genetic manipulation that would 
block their proliferation or sensitize them to radio- or 
chemo-therapy [11].
DNA repair pathways were extensively studied in car-
cinogenesis [12], because defects in these pathways ena-
ble tumor cells to accumulate mutations that enhance 
their proliferation and survival in the complex host tissue 
microenvironment. At the same time, these DNA repair 
deficiencies provide the rationale for exploring DNA-
damaging drugs for cancer treatment, because treatment 
with these drugs would cause cell-cycle arrest and con-
sequent cell death in DNA repair defective cancer cells. 
Following the same reasoning, cancer cells that maintain 
functional DNA repair pathways might be able to sur-
vive chemotherapy and/or radiation. For example, GBM 
patients are often treated with temozolomide, however 
the expression of the enzyme O6-Methylguanin-DNA-
Methyltransferase MGMT, which removes DNA adducts 
caused by the DNA alkylating drug temozolomide, makes 
the drug inefficient in the GBM patient population 
expressing MGMT. Interestingly, increased resistance 
of GBM cells to radiotherapy was suggested to be due to 
DNA damage response preferentially activated in GBM 
stem cells in comparison to their non-stem cells counter-
parts [13, 14]. However, the relevance of intrinsic DNA 
repair efficacy as a resistance mechanism of glioma stem 
cells remains elusive.
In the present study, we identified a panel of genes that 
are up-regulated in GSC vs GBM cells, isolated from the 
same patients. Out of these, we selected topoisomerase 
IIβ (Top2β) as the most significantly over-expressed in 
GSC samples. We show that the depletion of Top2β in 
glioma stem cells leads to increased sensitivity to a panel 
of replication stress-inducing drugs. This is associated 
with an increased load of DNA damage, consistent with 
the previously established role of Top2β in DNA damage 
repair.
Methods
Cell cultures
Glioblastoma (GBM) cell lines U87, U251 and T98G 
were purchased from American Tissue Cell Culture and 
grown in DMEM with 10 % FBS in 5 % CO2 atmosphere. 
Glioma stem cell line NCH421k was obtained from CLS 
cell lines service and grown as floating neurospheres in 
DMEM/F12 medium supplemented with 0.25  % BSA, 
1  % ITS, 20  ng/mL epidermal growth factor (EGF) and 
20  ng/mL basic fibroblast growth factor (bFGF). Nor-
mal neural stem cells (NSCs, Invitrogen) were grown in 
KnockOut™ DMEM⁄F-12 Basal Medium, StemPro® Neu-
ral Supplement, bFGF and EGF on Geltrex matrix as rec-
ommended by supplier (Invitrogen). Normal astrocytes 
were obtained from ScienCell Research Laboratories and 
grown in Astrocyte medium (ScienCell Research Labora-
tories) on poly-l-lysin coated plates.
Primary cell cultures from human GBM
After surgery tumors were histopathologically reviewed 
by two independent pathologists and in accordance 
WHO classification and recommendations. IDH status 
of glioblastoma tissues was evaluated by Therascreen 
IDH1/2 RGQ PCR Kit (Qiagen), following manufacturer 
instructions. All samples used in this study were IDH 
wild type.
GBM biopsies were mechanically and enzymati-
cally dissociated as described previously [15], and 
cells less than 40  μm in diameter were cultured both 
as primary glioblastoma cell culture (GBM) or in a 
GSC-promoting media. In the first case (primary GBM 
cell cultures), cells were cultured for 3 days in DMEM 
supplemented with 10 % FBS and 100 U/ml Penicillin 
100 μg/ml Streptomycin at 37  °C and 5 % CO2. Alter-
natively, the cells were grown under the culture con-
ditions promoting selective growth of glioblastoma 
stem cells (GSC) as neurospheres. Primary GSCs cul-
tures were seeded at a density of 2 × 105 cells in 5 ml 
of neural proliferation medium composed as follows: 
Neurobasal-A medium (Gibco), 2  mM  l-glutamine 
(Sigma-Aldrich), 1×  N2 supplement (Gibco), 25  μg/
ml Insulin, Penicillin–streptomycin, 100 μg/ml human 
apo-trasferrin (Sigma-Aldrich), 1×  B-27 supplement 
(Gibco), 20  ng/ml  h-FGF-basic (Peprotech), 20  ng/
ml h-EGF (Peprotech). GSCs were grown as floating 
neurospheres at 37  °C and 5  % CO2. Neurospheres 
were passaged when they reached approximately 100–
150 μm in diameter, by triturating them with a 200 μL 
micropipette until a homogenous single cell suspen-
sion was obtained. Neurospheres were analyzed after 
minimum three passages.
PCR‑array and RT‑PCR
RNA was isolated using Isol-RNA lysis reagent following 
manufacturer’s instructions (5Prime) and treated with 
DNase. Quality was examined spectrophotometrically 
and on agarose gel; 0.5  μg were transcribed to cDNA 
using cDNA Archive kit (Applied Biosystems). Expres-
sion of 60 DNA-repair related genes was measured using 
custom-made PCR-array (Bar Harbor Biotechnology); 
full list of genes is presented in the Additional file  1: 
Table S1. Quantitative RT-PCR reactions were performed 
on ABI Prism 7900 HT Sequence Detection System using 
SYBR Green master mix; internal controls were included 
in the array. PCR conditions were 50 °C for 2 min, 95 °C 
for 10 min and 45 cycles of 95 °C for 15 s and 60 °C for 
1 min; the data were analyzed by the ΔΔCt algorithm.
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Expression levels of Top2β and β-actin as endogenous 
control were measured by PCR (BioRad) using SYBR 
Green master mix (BioRad) and the following primer 
pairs (sequences selected from primerdepot NIH): 
β-actin F: ccttgcacatgccggag, R: gcacagagcctcgcctt; Top2β 
F: atggccaagtcgggtgg, R: tcatttttgttggcagtttctg; CD133 F: 
gcattggcatcttctatggtt, R: cgccttgtccttggtagtgt; nestin F: 
gggagttctcagcctccag R: ggagaaacagggcctacaga. Reaction 
conditions were the same as for the array.
Western blot
Cells were lysed in HNNG bufer (20 mM HEPES, pH 7.5, 
250  mM NaCl, 0.5  % NP-40, 10  % glycerol, 1  mM phe-
nylmethylsulfonyl fluoride [PMSF]) containing cocktail 
of protease (Roche) and phosphatase inhibitors (Sigma), 
10 μg of proteins from extracts were separated on poly-
acrylamide gels. Western blotting was performed as 
previously described using the following antibodies: 
anti-Top2β (Santa Cruz, 1:500), anti-GFAP (Novus Bio-
logicals, 1:5000), anti β-actin (Sigma, HRP-conjugated, 
1:10,000), anti p-Chk1 (Cell Signalling, 1:500), goat-anti 
mouse HRP-conjugated and goat anti-rabbit HRP-con-
jugated secondary antibody (Pierce, 1:5000). Western 
blots were developed with ECL Plus and Image quant 
LAS4000 imaging system (GE). Quantification was per-
formed using ImageJ software.
GSC differentiation induction
Differentiation of NCH421k neurospheres was induced 
as described previously [16] by growing them in the 
medium as described above, containing 10  % FBS and 
10 nM All -Trans-Retinoic Acid (ATRA) for the indicated 
time.
Top2β gene silencing
Top2β was downregulated using SmartPOOL RNA 
mix of 4 siRNAs (Dharmacon, CatN: L-004240-00) and 
HiPerfect transfection reagent (Qiagen). NCH421k neu-
rospheres or primary GSC spheres were broken to single 
cell suspension before transfection. Optimal downregu-
lation was achieved by double transfection with 50  nM 
siRNA and was stable between 48 and 120 h after trans-
fection. RNAi control experiments were performed using 
siRNA against Luciferase (Dharmacon).
Cell viability
Cell viability was measured using MTT assay. The 
drugs used were hydrogen peroxide (H2O2), temozo-
lomide (TMZ), methyl-methanesulfonate (MMS), cis-
platin (CisPt), camptothecin (CPT) and etoposide (all 
from Sigma). Stock solutions were prepared in DMSO 
and then diluted in cell media to the final concentra-
tions. Highest final concentration of DMSO was 0.025 % 
and was confirmed to have no effect on cell survival. 
Cisplatin (Sigma) stock solution was prepared in physi-
ological solution and diluted to applied final concentra-
tion. U251 or NCH421k cells or primary GSC cells were 
plated on 96-well plates at a density of 2000 cell per well 
and treated with indicated concentrations of replication 
stress inducing drugs for 72 h. MTT reagent was added 
at the final concentration of 5 mg/mL for 3 h. Plates were 
centrifuged, the violet formazan crystals were dissolved 
in DMSO and the absorbance was measured at the wave-
length 570 nm. Experiments were performed in triplicate 
(or in duplicate in the case of primary cells), statistical 
significance was determined by two-tailed Student’s t test 
and p < 0.05 was considered significant.
Immunofluorescence
NCH421k were transfected with anti-Luciferase siRNA 
(Luc) or siRNA against Top2β. Spheres were broken 
down to single cell suspension 72 h after transfection and 
treated with 50 μM CisPt or 200 μM MMS for 4 h. Cells 
were then fixed in 3.7  % PFA, permeabilized in 0.5  % 
Triton X100 and blocked in 3  % BSA. Antibodies used 
were anti-yH2AX (Santa Cruz, 1:300), 53BP1 (Novagen, 
1:500), Alexa Fluor 488 donkey anti-rabbit and Alexa 
Fluor 596 donkey anti-mouse (Invitrogen, 1:700). Cells 
were counterstained with Toto3 (1:10,000) and mounted 
in Vectashield. Images were acquired using Zeiss LSM 
510 Meta confocal microscope. Foci were counted with 
ImageJ ‘Analyze particles’ function. The average number 
of foci was obtained from three independent experiments 
analyzing at least 30 cells per sample.
Results
Top2β is upregulated in stem cell enriched cultures 
from primary glioblastoma samples
To test the hypothesis that DNA-repair pathways are 
involved in the specific resistance of GSC to chemother-
apy, we selected 60 DNA-repair genes and studied their 
expression in primary GBM cell cultures and in the stem 
cell-enriched populations (primary GSC) obtained from 
samples histologically confirmed to be GBM. Among 
these 60 genes, we included genes encoding for factors 
involved in key double-strand break and single-strand 
break DNA repair pathways, comprising factors involved 
in homologous recombination, non-homologous end 
joining, mismatch repair, nucleotide excision repair and 
DNA damage response.
We compared seven primary glioma cell cultures with 
five GSC-enriched primary cultures, out of those pairs 
three were coming from same patient. Gene expression 
was normalized to the 18S ribosomal RNA. Based on this 
analysis, we found 12 genes significantly up-regulated in 
GSC (Table  1). Among those, Top2β was up-regulated 
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with the highest fold change. Because of the known het-
erogeneity of GBM tumors [17], we have also compared 
the three matched samples—primary and GSC-enriched 
cultures obtained from the same patient. Considering 
only these sample pairs (Table  2), Top2β was still up-
regulated on the average of 2.8-fold with very high sig-
nificance p = 0.00077. In addition, MSH2 and RPA1 were 
up-regulated with a p < 0.005. We also performed a blind 
analysis, where expression is normalized to the genes that 
are selected with software of the PCR-array producer 
(Bar Harbor, not shown) and found that Top2β was again 
on the top of the list with the highest fold increase. Con-
sidering all these analysis, Top2β was selected for further 
studies. Top1 and Top2α were also included in the array, 
but their expression between primary GBM and GSC 
enriched cultures was not significantly different (data not 
shown).
Expression of Top2β was further validated by RT-PCR 
on five primary cultures of GBM and GSC of the same 
patient. The results confirmed the significant 1.8 ±  0.4-
fold (p  <  0.01) up-regulation of Top2β in GSC with 
respect to primary GBM cells.
Expression of Top2β in glioblastoma cell lines, normal 
neural stem cells and normal astrocytes
To further confirm that Top2β is selectively expressed in 
GSC, we analyzed its expression levels in different GBM 
cell lines such as U87, U251, and T98G as well as glioma 
stem cells NCH421k [both undifferentiated (abbrevi-
ated as NCH) and differentiated with all-trans retinoic 
acid (NCH-A)], normal neural stem cells (NSC), and 
normal human astrocytes. The latter two cell types are 
possibly present in GBM parenchyma and in the tumor 
microenvironment.
We confirmed that the expression of Top2β mRNA 
level was significantly higher in NCH421k cells than in all 
other tested cells (Fig. 1a). Specifically, Top2β expression 
was 5.2  ±  0.9-fold higher compared to GBM cells and 
1.8  ±  0.2-fold higher compared to normal neural stem 
Table 1 Expression of DNA repair related genes in primary 
GBM cultures and GSC-enriched neurospheres
p value and fold change of the genes that were significantly up-regulated in GSC 
compared to primary GBM cultures
Gene p value Fold change
BRCA1 0.011 3.933
PARP2 0.016 3.285
RPA1 0.017 2.569
LIG1 0.018 2.578
CHEK1 0.018 2.854
MSH3 0.020 2.154
XRCC5 0.021 2.559
CHEK2 0.023 2.971
RAD51 0.024 2.260
TOP2B 0.027 4.195
MSH2 0.035 2.250
XRCC1 0.043 2.324
Table 2 Expression in  GBM and  GSC samples originating 
from the same patient
p value and fold change for the expression of DNA repair related genes in GBM 
and GSC, when only matched samples were considered for analysis
Gene p value Fold change
MSH2 0.0004 2.760
TOP2B 0.0008 2.844
RPA1 0.0013 4.304
MSH3 0.0113 3.240
CHEK2 0.0116 4.080
LIG1 0.0122 5.817
XRCC5 0.0193 3.491
PARP2 0.0308 4.603
RAD51 0.0388 3.733
CHEK1 0.0472 2.539
Fig. 1 Expression of Top2β in different cell types. a Expression of 
Top2β at mRNA level in established GBM cell lines U87, U251, and 
T98G, established GSC cell line NCH421k (i.e. NCH) and ATRA-
differentiated NCH421k (i.e. NCH-A), normal human neural stem cells 
(NSC) and normal human astrocytes, measured by RT-PCR, expression 
normalized to β-actin, average ± SD is presented. b Top2β protein 
expression in established GBM and GSC cell lines as above, as deter-
mined using Western Blotting, where β-actin was used as loading 
control. The numbers below represent the quantitative expression of 
Top2β normalized to β-actin
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cells (Fig.  1a). Also, when we treated GSC with ATRA, 
which induces differentiation of GSC towards astro-
cytes (NCH-A), we found that the expression of Top2β 
decreased significantly to mean of 22.1 ± 8 % of the origi-
nal initial value. The expression of Top2β at protein level 
mirrored the results obtained at the mRNA level, being 
the highest in NCH421k cells (Fig. 1b).
To confirm that Top2β expression is related to GBM 
stemness, we induced GSC differentiation by exposing 
NCH421k cells to ATRA. We measured the progress of 
differentiation by the increasing expression of GFAP up 
to 120  h and found that simultaneously, the expression 
of Top2β progressively decreased (Fig.  2). Together with 
GFAP increase we detected also decrease in the expres-
sion of stemness markers CD133 and nestin [18]. In the 
opposite experiment, we down-regulated Top2β expres-
sion in NCH421k cells using siRNA to test whether its’ 
down-regulation alone induces differentiation. However, 
the expression of GFAP was not detected even after 5 days 
of Top2β depletion neither did Top2β depletion induce 
changes in expression of CD133 and nestin. In addition, 
the expression of GFAP was similar in control and Top2β 
depleted NCH421k cells both at 24 and 72 h after ATRA-
induction of differentiation (data not shown).
Top2β in glioma stem cells plays a role in DNA damage 
repair
To study the function of Top2β in GSC, we selected 
two cell types: the GBM U251 cells and GSC NCH421k 
cells, expressing the lowest and the highest Top2β lev-
els, respectively. We selected a panel of replication stress 
inducing drugs, namely camptothecin (CPT) and etopo-
side that are inhibitors of the topoisomerase 1 (Top1) 
and topoisomerase 2 (Top2), respectively. CPT primarily 
causes single strand break formation whereas etoposide 
induces double-strand break accumulation. We used 
also the cross-linking agent cisplatin (CisPt), the alkylat-
ing agents temozolomide and methyl methanesulfonate 
(MMS) that form different kind of DNA adducts, as well 
as hydrogen peroxide (H2O2) that induces both single 
and double strand breaks.
We used MTT assays to compare the sensitivity of U251 
and NCH421k cells to the selected drugs (Fig. 3). We found 
that U251 were more sensitive than NCH421k to hydrogen 
peroxide and CisPt within the entire concentration range, as 
well as to MMS, etoposide, and CPT at the indicated con-
centrations. This difference in the sensitivity disappeared 
upon Top2β depletion in NCH421k cells. Indeed, Top2β 
depletion (efficient depletion presented in the inset of Fig. 3) 
sensitized NCH421k cells to MMS, hydrogen peroxide, 
CisPt and CPT to sensitivity levels comparable to U251 cells 
and even further in the case of temozolomide. On the other 
hand, Top2β depletion had no significant effect on the sen-
sitivity to etoposide. Top2β was also downregulated in two 
primary GSC samples, which caused increased sensitivity to 
200 µM MMS and 50 µM CisPt (Fig. 4).
Increased DNA damage loading
The increased sensitivity detected in Top2β depleted 
NCH421k cells could be a consequence of an increased 
load of DNA damage and less efficient repair of DNA 
lesions upon genotoxic stress induction. To test this 
possibility, we have analyzed the extent of spontaneous 
and induced yH2AX foci in control or Top2β depleted 
NCH421k cells. DNA damage was induced either using 
200 μM MMS or 50 μM CisPt. The sensitivity to both of 
these drugs at this concentration was significantly differ-
ent for Top2β depleted and control cells. We found that 
in non-treated cells there was only a minor and statisti-
cally non-significant increase in the number of foci per 
cell—in fact, almost all cells were negative for yH2AX. 
However, when we induced DNA damage in Top2β 
depleted NCH421k cells we found that these cells had 
a 2-fold increase in the amount of yH2AX foci per cell 
(Fig. 5a, b). In particular, MMS treatment resulted in the 
formation of 4.2 ± 0.2 per control cell and 9.5 ± 1.1 foci 
per Top2β depleted cells. Similarly, the number of foci 
after CisPt treatment was 10  ±  0.6 in Top2β depleted 
cells, compared to 4.9 ±  0.6 in control cells. Also, both 
MMS and CisPt treatment induced stronger Chk1 activa-
tion in Top2β depleted cells (Fig. 5c).
Discussion
In the present study we show that Top2β, an ATP-
dependent enzyme that catalyzes topological changes 
of DNA, is highly expressed in glioblastoma stem cells. 
Enhanced Top2β expression in GSC was initially detected 
Fig. 2 Correlation of Top2β expression and differentiation. The 
expression of Top2β in NCH421k cells was measured at the indicated 
time points after ATRA-treatment; GFAP was used as a marker of dif-
ferentiation, β-actin was used as a loading control. Below the quantifi-
cation of Top2β expression normalized to actin
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among sixty DNA-repair related genes using PCR array 
comparing primary GBM cultures and GSC-enriched 
cultures. The same was then confirmed by RT-PCR. 
When we extended the same analysis to normal neural 
stem cells and astrocytes, possibly present in GBM and 
its parenchyma, we still found predominant expres-
sion of Top2β in GSC. The expression in GSC was also 
higher compared to the expression in established GBM 
Fig. 3 Top2β level dependent sensitivity to replication stress inducing drugs. Survival of U251 and NCH421k cells after exposure to increasing 
concentrations of selected drugs was determined by MTT assay as described in “Methods”. Drugs used were H2O2, CisPt, etoposide, CPT, MMS and 
TMZ. Green triangles U251 cells, blue diamond NCH421k control cells (siLuc), red squares NCH421k with Top2β down-regulation; average of three 
independent experiments ± SD is presented, asterisk indicates significance at p < 0.05. In the inset WB showing the efficiency of Top2β depletion in 
NCH421k cells
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cell lines. Moreover, when we treated stem cells with all-
trans retinoic acid (ATRA) that causes GSC differentia-
tion towards astrocytic phenotype, we found that Top2β 
expression was significantly decreased, strongly sug-
gesting that its increased expression was related to the 
stemness of GSC.
Top2β is expressed at a basal level in most cells and tis-
sues, including fully-differentiated cerebellum, myome-
trium and pancreas, or tissues with high cell turnover, 
such as the endometrium, skin, and bowel mucosa [19]. 
It has also been shown that the levels of Top2β do not 
vary much during the cell cycle, even though the protein 
seems to be differentially phosphorylated during the dif-
ferent cell cycle phases [20]. Interestingly, Top2β expres-
sion was also found to decrease with aging, in fact it was 
almost absent in senescent cerebral granule neurons [21]. 
Reports on the level of Top2β expression in cancer are 
very limited. The enzyme was shown to be increased in 
locally advanced prostate cancer [22]. Top2β expression 
in GBM and/or in GSC has not been thoroughly inves-
tigated so far. However, the publically available Reposi-
tory for Molecular Brain Neoplasia Data (Rembrandt) 
(http://caintegrator.nci.nih.gov/rembrandt/) evidences 
the expression of Top2β in glioma, although it does not 
correlate with increasing glioma malignancy. Our finding 
demonstrated higher expression of Top2β in GSCs which 
are reportedly more abundant in high grade glioma [23] 
and correlate with worse prognosis [24]. Therefore, we 
posit that there should be a positive correlation of Top2β 
with malignancy, but future measurements of the expres-
sion of Top2β in low grade glioma would be necessary to 
support this conclusion.
Following the idea that GBM stem cells are more resist-
ant to chemotherapeutics because of their increased effi-
ciency of DNA repair, we investigated whether increased 
expression of Top2β is one of the underlying reasons for 
this phenomenon. First, we have compared the sensitiv-
ity of cells with endogenously low (GBM cells U251) and 
high (GSC cells NCH421k) Top2β expression to selected 
DNA damage inducing drugs. We indeed found that 
U251 cells were more sensitive to CisPt, MMS, etopo-
side and H2O2 compared to NCH421k cells. Next, we 
confirmed that down-regulation of Top2β in NCH421k 
cells increases their sensitivity to these drugs to the same 
level as detected in U251 cells. Similar increase in sensi-
tivity to MMS and CisPt was observed in the two sam-
ples of primary GSC. To determine why Top2β deficient 
cells are more sensitive to drug treatment, we have also 
looked at the level of DNA damage by monitoring the 
phosphorylated form of histone 2AX (yH2AX), which 
is a hallmark of DNA breaks/damage. In both MMS 
and CisPt treatments, we found that the level of DNA 
damage was increased. Also, the checkpoint kinase 1 
(CHK1) was increasingly activated upon downregulation 
of Top2β. Results are consistent with previous findings 
showing increased sensitivity to H2O2 in astrocytoma cell 
line [25] and to N-ethyl N-nitroso urea in granule neu-
rons [26] after Top2β silencing. Moreover, Emmons et al. 
[27] showed the crosslinking agent melphalan induces 
an increased level of crosslinks, which lead to apoptosis. 
Increased sensitivity to genotoxic agent, together with 
increased accumulation of DNA damage was detected 
also in ovarian granulosa cells depleted for Top2β [28]. 
Interestingly, Top2β levels had no noticeable effect on 
sensitivity to etoposide. This could be a consequence of 
a partial (but not complete) overlap of the Top2β func-
tion with the function of Top2α. Top2α is a direct target 
of etoposide and cells lacking this enzyme are resist-
ant to etoposide treatment. The hypothesis that Top2β 
might have a partially overlapping function with Top2α 
Fig. 4 Sensitivity of primary GSC to MMS and CisPt. Top2β was depleted in primary GSC cultures from 2 different patients (sample 1 and 2). Cells 
were treated with 200 µM MMS or 50 µM CisPt and survival was determined by MTT assay. Average of 2 independent experiments ± SD is pre-
sented
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is supported by previous reports showing that the two 
isoforms of Top2 (170 kDa alpha and 180 kDa beta) have 
similar enzymatic properties, although they differ in their 
in  vivo expression patterns [20]. Top2β might also have 
specific functions distinct from those of Top2α consistent 
with previous reports, showing that etoposide cytotox-
icity depends on Top2α, whereas genotoxicity (chromo-
somal breaks and rearrangements) is Top2β dependent 
[29]. Also, alkylating agents induced increased levels of 
cross-links in Top2β down-regulated cells, but not in 
Top2α down-regulated cells [27]. Of note, we did not 
detect any significant changes in the expression of other 
topoisomerases, including Top1 or Top2α. These results 
suggest that the observed increase in Top2β expression is 
not a compensatory response connected to deficiencies 
in other topoisomerase enzymes, as was previously dis-
cussed in some contradictory studies [30, 31].
Top2β plays a major role in quiescent (non-S-phase) 
mouse embryonic fibroblasts exposed to high (μM) CPT 
concentrations [32]. This was explained with the inabil-
ity of Top2β depleted cells to replace RNA polymerase 
II large subunit that is degraded after CPT treatment. In 
our study, we did not find a major increase in sensitivity 
of Top2β downregulated cells to CPT. A possible expla-
nation is that we have used low concentrations of drugs 
with the idea to focus on concentrations that would be 
potentially useful also under physiological conditions. In 
case of CPT, we have used concentrations up to 25 nM 
that have an effect only on replicating cells but not on 
postmitotic (G1 or quiescent) cells [33] and therefore do 
not induce significant cell death.
Top2β has also been implicated in cell differentiation. 
This is particularly important during neuronal develop-
ment, where Top2β induces the transcription of differ-
entiation related genes through modulation of chromatin 
structure [34, 35]. Specifically, the signal-dependent acti-
vation of gene transcription by nuclear receptors and 
other classes of DNA binding transcription factors 
Fig. 5 Increased load of DNA damage in Top2β depleted cells. a DNA damage was induced using 200 μM methyl-methanesulphonate (MMS) or 
50 μM cisplatin (CisPt) in control (Luc) and Top2β down-regulated NCH421k cells. Cells were stained for yH2AX (red) and counterstained with Toto3 
(blue). Representative images are shown, scale bar 10 µm. b Number of foci per cell was quantified as described in “Methods” and is presented as 
the average of three experiments ± sd. c Chk1 activation after MMS and CisPt treatment, tubulin is a loading control. Below quantification of pChk1 
normalized to tubulin
Page 9 of 10Kenig et al. Cancer Cell Int  (2016) 16:58 
requires Top2β-dependent, transient, site-specific dsDNA 
break formation [36]. Also, Top2β knockout mice have 
impaired expression of genes involved in later stages of 
neuronal differentiation [37]. GSC differentiation was 
recently suggested as a promising treatment modality, due 
to impairing the known resistance mechanisms of stem 
cells. Given that Top2β is over-expressed in cancer stem 
cells, we also investigated whether Top2β depletion might 
influence differentiation possibly through modulation 
of herby relevant genes. However, we found that Top2β 
down-regulation per se was not sufficient to induce dif-
ferentiation of GSC. It also neither blocked nor enhanced 
ATRA-induced differentiation. The effect is likely cell type 
specific, because Top2β has been shown to repress ATRA 
induced differentiation of acute promyelocytic leukemia 
cells towards granulocytes [38].
In addition to Top2β, we also found other genes upreg-
ulated in primary cultures of GSC cells, compared to 
primary GBM cultures. In particular, replication protein 
A1 (RPA1) and MutS homolog2 (MSH2) were up-regu-
lated with high significance. MSH2 is a protein involved 
in mismatch repair but its role in GBM drug sensitiv-
ity has never been investigated in detail. High levels 
of MSH2 correlated with glioma malignancy [39] and 
were detected in multi-resistant malignant gliomas [40]. 
However, a minor downregulation of MSH2 was found 
to cause drastic increase in the resistance to temozolo-
mide [41]. RPA1 is a part of replication protein A com-
plex, and has thus far not been studied in GBM. It was 
however found to have prognostic value in some other 
types of cancer, such as colon [42]. Further work would 
be necessary to clarify the function of these additional 
DNA repair genes in GSC cells. These studies would be 
important because the proteins coded by these genes 
might also contribute to the drug-resistant phenotype of 
GBM.
Conclusions
Taken together, our results indicate that Top2β is associ-
ated with GBM resistance to chemotherapy and supports 
its stemness characteristics. As such, we posit that Top2β 
might represent a novel GSC biomarker for diagnosis of 
therapy resistant tumors and could be used in predic-
tion to GBM therapy response. By the same token, this 
enzyme can also be target for therapy (so called thera-
nostic), which alone or in combination with other targets, 
would reduce the GBM stemness, allowing the use of 
lower doses of chemotherapeutics to eliminate the tumor.
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